<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04827992</url>
  </required_header>
  <id_info>
    <org_study_id>2021P000871</org_study_id>
    <nct_id>NCT04827992</nct_id>
  </id_info>
  <brief_title>Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain</brief_title>
  <official_title>Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will use a randomized controlled design to test whether medical marijuana use by&#xD;
      adults on high-dose chronic opioid therapy (COT) for chronic non-cancer pain (CNCP) is&#xD;
      associated with reduced opioid dose and improved pain severity when added to a 24-week&#xD;
      behavioral intervention (POTS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a randomized, six-month study of medical marijuana (MM) on opioid use that&#xD;
      will: (1) evaluate whether adults with CNCP on COT assigned to MM+POTS, compared with those&#xD;
      assigned to WL+POTS, have greater reduction in opioid dose and/or pain severity, (2) assess&#xD;
      whether participants assigned to MM+POTS, compared with those assigned to WL+POTS, have&#xD;
      improved quality of life, improved pain interference, depression, and anxiety; and&#xD;
      improvement in cognitive functioning, (3) evaluate whether those assigned to MM+POTS develop&#xD;
      symptoms of CUD over the 24-week intervention, as well as at the 12-month time point.&#xD;
&#xD;
      Participants will be randomly assigned to either an active MM arm (n = 125), or to a waitlist&#xD;
      control arm (WLC) (n = 125). Participants will be assessed at baseline, every 4 weeks for 6&#xD;
      months, and at a 12-month follow-up for opioid use, development of CUD, development or&#xD;
      resolution of OUD, and neurocognitive performance. Urine collected at each visit will be&#xD;
      assessed with quantitative assays.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Opioid Use</measure>
    <time_frame>Change from baseline to 6 Month</time_frame>
    <description>The opioid dose (MME/day) will measure any change in use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Pain Severity</measure>
    <time_frame>Change from baseline to 6 Month</time_frame>
    <description>The pain severity sub-scale of the Brief Pain Inventory - Short Form will assess pain severity symptoms. The scale ranges from 0 - 40, with a higher score indicating greater pain severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life</measure>
    <time_frame>Change from baseline to 6 Month</time_frame>
    <description>Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form will assess changes in quality of life measures. The scale ranges from 14 - 70, with a lower score indicating greater dissatisfaction with life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Pain Interference</measure>
    <time_frame>Change from baseline to 6 Month</time_frame>
    <description>The pain interference sub-scale of the Brief Pain Inventory - Short Form will assess pain interference symptoms. The scale ranges from 0 - 70, with a higher score indicating greater pain interference.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Depression</measure>
    <time_frame>Change from baseline to 6 Month</time_frame>
    <description>The depression sub-scale of the PROMIS-29 will be used to assess depression symptoms. The scale ranges from 0 - 21, with a higher score indicating greater depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Anxiety</measure>
    <time_frame>Change from baseline to 6 Month</time_frame>
    <description>The anxiety sub-scale of the PROMIS-29 will be used to assess anxiety symptoms. The scale ranges from 0 - 21, with a higher score indicating greater anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Opioid Use Disorder</measure>
    <time_frame>Change from baseline to 6 Month</time_frame>
    <description>The DSM-5 Opioid Use Disorder Checklist will evaluate symptoms of Opioid Use Disorder (number of symptoms). The scale ranges from 0 - 11, with a higher score indicating more severe Opioid Use Disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Cannabis Use Disorder</measure>
    <time_frame>Change from baseline to 6 Month</time_frame>
    <description>The DSM-5 Cannabis Use Disorder Checklist will evaluate symptoms of Cannabis Use Disorder (number of symptoms). The scale ranges from 0 - 11, with a higher score indicating more severe Cannabis Use Disorder.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in Cognitive Functioning: verbal memory</measure>
    <time_frame>Change from baseline to 6 Month</time_frame>
    <description>Verbal learning will be assessed through the CVLT-III</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Cognitive Functioning: attention</measure>
    <time_frame>Change from baseline to 6 Month</time_frame>
    <description>Attention will be assessed using the Connors CPT</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Cognitive Functioning: working memory</measure>
    <time_frame>Change from baseline to 6 Month</time_frame>
    <description>Working memory will be assessed using the WAIS</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Opioid Use</condition>
  <condition>Pain</condition>
  <condition>Marijuana Use</condition>
  <arm_group>
    <arm_group_label>Medical Marijuana + Prescription Opioid Taper Support (POTS) behavioral treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group can begin using medical marijuana immediately and will participate in the POTS treatment groups.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prescription Opioid Taper Support (POTS) treatment alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group must abstain from marijuana use and will participate in the POTS behavioral treatment alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medical Marijuana</intervention_name>
    <description>Patients in this group can choose what type, how much, and when to use medical marijuana to use.</description>
    <arm_group_label>Medical Marijuana + Prescription Opioid Taper Support (POTS) behavioral treatment</arm_group_label>
    <other_name>Cannabis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Prescription Opioid Taper Support (POTS)</intervention_name>
    <description>Prescription Opioid Taper Support (POTS), a manualized behavioral prescription opioid taper support intervention developed by consultant, will be offered weekly to all participants to support behavioral self-management of pain and structured, voluntary taper of COT dose.</description>
    <arm_group_label>Medical Marijuana + Prescription Opioid Taper Support (POTS) behavioral treatment</arm_group_label>
    <arm_group_label>Prescription Opioid Taper Support (POTS) treatment alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women aged 18-75, inclusive.&#xD;
&#xD;
          2. Endorsing &gt; 6 months of CNCP.&#xD;
&#xD;
          3. On stable prescription opioid doses of at least 25 MME for &gt;90 days.&#xD;
&#xD;
          4. Either no prior use or current light cannabis use (weekly or less in the past 12&#xD;
             months).&#xD;
&#xD;
          5. Desire to use medical cannabis for pain to control pain and/or reduce opioid dose.&#xD;
&#xD;
          6. Competent and willing to provide written informed consent in English.&#xD;
&#xD;
          7. Potential participants of childbearing potential must have a negative urine pregnancy&#xD;
             test at enrollment and agree to use effective contraception: abstinence; hormonal&#xD;
             contraception; intra-uterine device, sterilization; or double barrier contraception,&#xD;
             during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current cannabis use of greater than weekly on average in the past 12 months, assessed&#xD;
             via self-report.&#xD;
&#xD;
          2. Current major medical illness, such as cancer, symptomatic&#xD;
             hypothyroidism/hyperthyroidism or severe respiratory compromise.&#xD;
&#xD;
          3. Use of non-prescribed opioids, by self-report or urine toxicology screen.&#xD;
&#xD;
          4. Actively suicidal and/or suicide attempt or psychiatric hospitalization in past year,&#xD;
             or current suicidal ideation with specific plan or intent.&#xD;
&#xD;
          5. History of intellectual disability (e.g., Down's syndrome) or other severe&#xD;
             developmental disorder or IQ &lt; 70.&#xD;
&#xD;
          6. Current diagnosis of delirium, dementia, amnestic, or other cognitive disorder;&#xD;
             lifetime schizophrenia or other psychotic disorder; bipolar I disorder; clinically&#xD;
             significant diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or&#xD;
             histrionic personality disorder.&#xD;
&#xD;
          7. Surgery within the past month or planned during the next 6 months.&#xD;
&#xD;
          8. Pregnant or trying to get pregnant or breastfeeding.&#xD;
&#xD;
          9. In the opinion of the investigator or study physicians, not able to safely participate&#xD;
             in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jodi Gilman, PhD</last_name>
    <phone>6176437293</phone>
    <email>jgilman1@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2523</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodi Gilman</last_name>
      <phone>617-643-7293</phone>
      <email>jgilman1@partners.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Jodi Gilman</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Opioid</keyword>
  <keyword>Marijuana</keyword>
  <keyword>Pain</keyword>
  <keyword>neurocognition</keyword>
  <keyword>Dependence</keyword>
  <keyword>Behavioral treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Marijuana Use</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

